|
|
|
|
|
17.04.26 - 14:36
|
Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer (Business Wire)
|
|
|
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that all required regulatory approvals have been obtained for its previously announced acquisition of Arcellx and that Gilead has extended the expiration of the tender offer to purchase all outstanding shares of common stock of Arcellx.
On April 13, 2026, the Australian Competition and Consumer Commission (ACCC) published its decision that the acquisition of Arcellx may be put into effect, subject to expiration of a 14-calendar day waiting period. Assuming that the ACCC's determination remains unchallenged during this waiting period, the waiting period expires at 10:00 a.m., Eastern Time, on April 27, 2026. Additionally, the relevant review period for the Austrian competition authorities has expired. Accordingly, all required regulatory approvals for the transaction have been obtained, and the “Regulatory Approvals Condition” (as defined in the Offer to Purchase, dated March 6, 2026, relating to the offer) will...
|
|
|
|
|
|
|
|
|
14.04.26 - 18:06
|
PEPFAR and The Global Fund Make Additional Investment in Gilead′s Lenacapavir for HIV Prevention to Further Expand Access (Business Wire)
|
|
|
– Additional Commitment will Expand Access to Lenacapavir to Reach Another Million People Over the Next 3 Years –FOSTER CITY, Calif.--(BUSINESS WIRE)--#EndHIV--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. State Department, the United States President's Emergency Plan for AIDS Relief (PEPFAR) and The Global Fund will further invest in Gilead's twice-yearly injectable HIV prevention medicine, lenacapavir, to expand access for up to an additional 1 million people, bringing the total commitment up to 3 million people in high-incidence, resource-limited countries through 2028.
Bringing together the resources and expertise of both PEPFAR and The Global Fund is a key component of Gilead's larger coordinated efforts to advance access to lenacapavir for HIV PrEP. These partners are experts in country delivery and distribution, with the reach and infrastructure to ensure these supplies reach those with the greatest need as quickly as possible. Lenacapavir is the first HIV prevention the...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
08.04.26 - 21:54
|
Gilead to Buy Cancer Biotech Tubulis in $5B Deal (Bloomberg)
|
|
|
Bloomberg's Michelle Davis joins Dani Burger on "Bloomberg Deals." Gilead agreed to buy private German biotech Tubulis in a deal worth up to $5 billion as it looks to boost its portfolio in a hot new area of cancer drug development. (Source: Bloomberg)...
|
|
|
|
|
08.04.26 - 11:00
|
Gilead übernimmt Tubulis und erweitert damit seine Onkologie-Pipeline (Moneycab)
|
|
|
München – Gilead Sciences, Inc. (Nasdaq: GILD) gab bekannt, dass es eine endgültige Vereinbarung zur Übernahme der Tubulis GmbH geschlossen hat, eines privaten deutschen Biotechnologieunternehmens im klinischen Stadium, das Antikörper-Wirkstoff-Konjugate (ADCs) der nächsten Generation entwickelt und dabei auf Gileads Onkologie-Pipeline aufbaut. Die Übernahme erweitert die ADC-Kompetenzen von Gilead erheblich durch die Einbindung von Wirkstoffen und […]...
|
|
|
08.04.26 - 11:00
|
Gilead Sciences übernimmt ADC-Unicorn Tubulis für bis zu 5 Mrd. USD (GoingPublic)
|
|
|
Gilead Sciences baut sein Engagement im Bereich Onkologie deutlich aus: Der US-Pharmakonzern übernimmt die Münchener Biotechfirma Tubulis für bis zu 5 Mrd. USD. Davon entfallen 3,15 Mrd. USD auf sofort […]
Der Beitrag Gilead Sciences übernimmt ADC-Unicorn Tubulis für bis zu 5 Mrd. USD erschien zuerst auf GoingPublic.de....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
